Search

Search Results

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  1951

  PDF: 776

  HTML: 196

• Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio

  Dr. Enrica A. Martino, Dr. G. Mele, Dr. F. Morabito, Dr. M. Gentile, Dr. E. Vigna

  e2025006

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.006

  2074

  PDF: 1524

  HTML: 248

• Skin Involvement in Primary Systemic Amyloidosis

  susheel kumar

  e2013005

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.005

  1542

  PDF: 865

  HTML: 4345

  Figure 1. Photographs showing (a) enlarged tongue with (b) teeth marks over the lateral margin and (c, d) multiple, papular lesions over lower chest wall: 158

  Figure 2. Microphotograph showing pink eosinophilic homogenous material in the dermis, H&E X 20: 117

  Figure 3. Pink eosinophilic material showing pale orange positivity with Congo red stain: 157

• MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

  Francesca Fazio, Gianfranco Lapietra, Maria Zaira Limongi, Stefania Intoppa, Maria Laura Milani, Alfonso Piciocchi, Maurizio Martelli, Anna Guarini, Robin Foà, Maria Stefania De Propris, Maria Teresa Petrucci

  e2023047

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.047

  905

  PDF: 658

  HTML: 259

• POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE

  Guillermo Jose Ruiz-Delgado, Avril Lopez-Otero, Ana Hernandez-Arizpe, Aura Ramirez-Medina, Guillermo Jose Ruiz-Argüelles

  e2010016

  2010-06-19

  https://doi.org/10.4084/mjhid.2010.016

  1134

  PDF: 712

  HTML: 568

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1442

  PDF: 1129

  HTML: 171

• MONOCYTE ADHESION MOLECULES EXPRESSION IN PATIENTS WITH CHRONIC HEPATITIS C AND LIVER CIRRHOSIS

  Nora E.I. El-Bassiouni, Ola Mahmoud Mahmoud, Eman G El Ahwani, Raafat A. Ibrahim, Azza E.I. El Bassiouny

  e2013054

  2013-09-01

  https://doi.org/10.4084/mjhid.2013.054

  1066

  PDF: 577

  HTML: 912

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  1982

  PDF: 1599

  HTML: 345

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  1869

  PDF: 705

  HTML: 677

• COVID-19 induces prolonged immunological exhaustion leading to relapse of hematological malignancies except in hematopoietic cell transplant recipients

  SUPARNO CHAKRABARTI, Snigdha Banerjee, Mahak Agarwal, Gitali Bhagawati, Nilanjan Saha, SARITA JAISWAL

  e2025042

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.042

  952

  PDF: 671

  HTML: 97

• HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

  Giovanna Cannas, Solene Poutrel, Xavier Thomas

  e2017015

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.015

  3833

  PDF: 1126

  HTML: 1637

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  1936

  PDF: 1067

  HTML: 166